Squarepoint Ops LLC Takes $1.70 Million Position in Regencell Bioscience Holdings Limited $RGC

Squarepoint Ops LLC acquired a new stake in Regencell Bioscience Holdings Limited (NASDAQ:RGC) in the second quarter, Holdings Channel.com reports. The fund acquired 99,843 shares of the company’s stock, valued at approximately $1,701,000.

A number of other institutional investors also recently bought and sold shares of RGC. Greenfield Savings Bank acquired a new position in Regencell Bioscience in the 2nd quarter valued at about $187,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Regencell Bioscience during the 2nd quarter valued at approximately $222,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience in the second quarter valued at approximately $768,000. Finally, Geode Capital Management LLC grew its position in Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after acquiring an additional 384,250 shares during the period. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Trading Up 4.7%

Shares of RGC stock opened at $19.81 on Friday. The business has a 50 day moving average of $15.00. Regencell Bioscience Holdings Limited has a one year low of $0.09 and a one year high of $83.60.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Regencell Bioscience Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.